Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-115A vs AD-1151 bioequivalence study in healthy volunteers
NCT06902818Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of revaprazan in gastric ulcer (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Plasma Concentration-Time Curve at 24 hours. Started Mar 2025; status: completed.
02
Drugs
revaprazan
03
Conditions
gastric ulcer
Beyond the preview
Go deeper on NCT06902818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902818.